Psoriatic Arthritis Treatment Market Report 2025

This Psoriatic Arthritis Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The psoriatic arthritis treatment market size has grown strongly in recent years. It will grow from $10.93 billion in 2024 to $12 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increased diagnosis, rising prevalence of psoriatic arthritis, increasing awareness of psoriatic arthritis and its treatments, expanding range of approved psoriatic arthritis treatments, government support for research and development, increased investment from pharmaceutical companies.

The psoriatic arthritis treatment market size is expected to see strong growth in the next few years. It will grow to $17.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to personalized medicine, emerging biologics and small molecules, expanding treatment options, global aging population. Major trends in the forecast period include advancements in biologics, oral small molecules, targeting specific pathways, telemedicine and remote monitoring, patient-centered care, and real-world evidence.

The growing prevalence of psoriasis and psoriatic arthritis has significantly contributed to the expansion of the psoriatic arthritis treatment market. Psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory conditions that can severely affect health and quality of life. Approximately 30% of individuals with psoriasis also experience psoriatic arthritis. For example, in January 2024, reports from the National Library of Medicine, a US government agency, indicated that the annual incidence of psoriatic arthritis among patients with psoriasis ranges from 1.9% to 2.7% per 100 patients. Over time, the risk of developing PsA increases notably, with incidence rates of 1.7% at five years, 3.1% at ten years, and reaching as high as 20.5% at thirty years after a psoriasis diagnosis. Therefore, the rising incidence of psoriasis and psoriatic arthritis is a key driver of market growth.

The surge in healthcare spending has propelled the growth of the psoriatic arthritis treatment market. Increased healthcare expenditure supports various diagnostic procedures, including medical appointments, laboratory tests, and imaging studies essential for confirming diagnoses like psoriatic arthritis. For instance, in the UK, healthcare spending reached around $347.74 billion in 2022, demonstrating a 0.7% nominal increase from the previous year. This increased investment in healthcare resources contributes to the growth of treatments for conditions like psoriatic arthritis.

Leading companies in the psoriatic arthritis treatment market are increasingly concentrating on developing advanced products, such as targeted biologic therapies, to provide more effective and personalized treatment options. These therapies aim to address the underlying inflammatory processes, improve patient outcomes, and enhance the overall quality of life for individuals living with this chronic condition. Targeted biologic therapy involves using specially designed drugs or substances that interfere with specific molecules involved in the growth and spread of disease, aiming to minimize damage to normal cells while maximizing therapeutic efficacy. For example, in January 2022, AbbVie, a US-based biopharmaceutical company engaged in discovering and developing medicines, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa). SKYRIZI is an interleukin-23 inhibitor specifically indicated for the treatment of active psoriatic arthritis, targeting inflammation at its source by blocking the p19 subunit of IL-23. Clinical studies have shown significant improvements in joint symptoms and overall disease activity, with many patients achieving clinical remission and enhanced quality of life. Administered through subcutaneous injection, this therapy provides a convenient option for patients, allowing for flexible dosing schedules tailored to their individual needs.

Major pharmaceutical companies have also been instrumental in market growth by introducing new drugs like Cosentyx. This drug, developed by Novartis, is an interleukin-17A antagonist used to treat various autoimmune diseases, including psoriatic arthritis. In October 2023, its approval by the FDA marked a significant milestone, offering relief for symptoms like joint pain and skin problems associated with psoriatic arthritis.

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company acquired Nimbus Therapeutics for an undisclosed amount. The acquisition is anticipated to improve Takeda Pharmaceutical's position in the market for psoriatic arthritis treatments and broaden its product line. Nimbus Therapeutics is a US-based biotechnology company. It develops drugs for psoriatic arthritis treatment.

Psoriatic arthritis treatment aims to mitigate or halt the progression of a chronic inflammatory condition affecting joints and the areas where tendons and ligaments attach to bones (entheses). This treatment regimen concentrates on managing skin involvement, alleviating joint pain, and addressing associated disability.

The primary classes of drugs used in psoriatic arthritis treatment encompass nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and other medications. Biologic medicines, a subset of treatment options, are substances derived from or containing components of living organisms. These medications can be administered through various routes, including oral, parenteral (injection or infusion), and topical applications. They are distributed through diverse channels such as hospital pharmacies, retail pharmacies, and online pharmacies to cater to the needs of patients undergoing psoriatic arthritis treatment.

The psoriatic arthritis treatment market research report is one of a series of new reports that provides psoriatic arthritis treatment market statistics, including global market size, regional shares, competitors with a psoriatic arthritis treatment market share, detailed psoriatic arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the psoriatic arthritis treatment industry. This psoriatic arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the psoriatic arthritis treatment market include AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., CB Biosciences Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Abbott Laboratories, Eisai Inc., Janssen Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, LEO Pharma A/S, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

North America was the largest region in the psoriatic arthritis treatment market in 2024. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The psoriatic arthritis treatment market includes revenues earned by entities by reducing pain and swelling and controlling inflammation and pain. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.